Frontiers in pharmacology · 2026
Novel anxiolytic-antidepressant combinations TF-1 and TF-2 and their intervention mechanisms in a mouse model of comorbid anxiety and depression (CAD).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Min, Wang Yuxiang, Li Zheng, Li Rongzhu, Wang Liu, Sheng Lin, Shi Peng, Zuo Ying, Wei Yumeng, Zhao Ling
Аннотация
BACKGROUND AND OBJECTIVE: To address the high mortality, slow onset, and suboptimal efficacy of current treatments for comorbid anxiety and depression (CAD), this study developed and systematically evaluated a novel combination formulation.
METHODS: The anxiolytic tandospirone (TDS) was combined with fluoxetine (FLU), escitalopram, or milnacipran for cell-based screening. The optimal combination was selected for pharmacokinetic studies in rats, followed by a 49-day pharmacodynamic evaluation and mechanistic investigation in a CAD mouse model.
RESULTS: Two optimal TDS-FLU combinations, TF-1 (TDS:FLU = 1.2:1,w/w) and TF-2 (TDS:FLU = 2.4:1,w/w), were obtained, both exhibiting good neuroprotective effects. Pharmacokinetic results showed that TF-1 and TF-2 significantly increased drug exposure and prolonged half-life compared with monotherapies of TDS and FLU. Pharmacodynamically, TF-1 and TF-2 exhibited superior anxiolytic-antidepressant efficacy compared with monotherapies after 28-day and 49-day interventions. At day 28, both formulations significantly increased open-field central-zone activity and sucrose preference, and reduced immobility time (all P < 0.05). Their therapeutic benefits were further augmented at day 49, with sustained and improved behavioral improvements upon long-term treatment. Mechanistic studies showed that both combinations elevated plasma and hippocampal 5-HT and BDNF levels, upregulated hippocampal 5-HT1AR and TrKB expression, and enhanced neuronal plasticity.
CONCLUSION: TF-1 and TF-2 were superior to single agents in pharmacokinetics and long-term CAD efficacy, acting via 5-HT modulation and BDNF-TrKB activation, supporting their development as CAD combination therapies.
METHODS: The anxiolytic tandospirone (TDS) was combined with fluoxetine (FLU), escitalopram, or milnacipran for cell-based screening. The optimal combination was selected for pharmacokinetic studies in rats, followed by a 49-day pharmacodynamic evaluation and mechanistic investigation in a CAD mouse model.
RESULTS: Two optimal TDS-FLU combinations, TF-1 (TDS:FLU = 1.2:1,w/w) and TF-2 (TDS:FLU = 2.4:1,w/w), were obtained, both exhibiting good neuroprotective effects. Pharmacokinetic results showed that TF-1 and TF-2 significantly increased drug exposure and prolonged half-life compared with monotherapies of TDS and FLU. Pharmacodynamically, TF-1 and TF-2 exhibited superior anxiolytic-antidepressant efficacy compared with monotherapies after 28-day and 49-day interventions. At day 28, both formulations significantly increased open-field central-zone activity and sucrose preference, and reduced immobility time (all P < 0.05). Their therapeutic benefits were further augmented at day 49, with sustained and improved behavioral improvements upon long-term treatment. Mechanistic studies showed that both combinations elevated plasma and hippocampal 5-HT and BDNF levels, upregulated hippocampal 5-HT1AR and TrKB expression, and enhanced neuronal plasticity.
CONCLUSION: TF-1 and TF-2 were superior to single agents in pharmacokinetics and long-term CAD efficacy, acting via 5-HT modulation and BDNF-TrKB activation, supporting their development as CAD combination therapies.